Regiodeal Arnhem-Nijmegen van start

Minister Hugo de Jonge geeft officieel startsein voor Regio Deal

De Regio Deal van de regio Arnhem-Nijmegen is op 1 november ondertekend tijdens een feestelijke bijeenkomst in Ede. Deze Regio Deal richt zich op de aanpak van belangrijke opgaven en verbetering van de kwaliteit van leven, wonen en werken van inwoners en ondernemers (zgn. brede welvaart) in de regio Arnhem-Nijmegen. Het Rijk en de regio zetten met deze Regio Deal in op een ‘Gezonde groene groei’ door oplossingen voor de grote en lastige opgaven in de zorg, woningbouw, economie en arbeidsmarkt. Deze Regio Deal is een van de veertien nieuwe deals uit de vierde ronde. Minister De Jonge (Binnenlandse Zaken en Koninkrijksrelaties, Volkshuisvesting en Ruimtelijke Ordening) gaf tijdens de bijeenkomst het officiële startsein voor alle Regio Deals uit de vierde tranche.

Hubert Bruls, voorzitter Groene Metropoolregio Arnhem-Nijmegen (samenwerking van de 18 gemeenten) is verheugd over de bijdrage van het Rijk. “De regio Arnhem-Nijmegen is de vijfde Metropoolregio van Nederland. Door onder andere de gunstige ligging en aantrekkelijke omgeving groeien we de komende decennia nog verder. Dat willen we op een gezonde en groene manier doen.”

Regio Deal Gezonde groene groei

Om de hele regio op een gezonde en groene manier te laten groeien, zet de Regio Deal ook in op het verbeteren van de welvaart voor inwoners in wijken en dorpen waarin de leefbaarheid onder druk staat. De Regio Deal is gericht op een gezonde groene groei door kennis, talent, innovatiekracht en ecosystemen in de regio te benutten om opgaven sneller, completer en grootschaliger aan te pakken. Ahmed Marcouch, voorzitter The Economic Board Regio Arnhem Nijmegen: “Deze Regio Deal zorgt ervoor dat wij vooruit kunnen met cruciale innovaties en ontwikkelingen in de zorg, woningbouw, bedrijventerreinen en arbeidsmarkt. Zo kunnen wij de kwaliteit van leven, wonen en werken verbeteren.”

Samenwerken loont

Dirk Vreugdenhil, Gedeputeerde provincie Gelderland: ”Regio Arnhem-Nijmegen is de vijfde regio van Nederland. Maar we staan ook in de top met de hoogste woningtekorten, de meeste files en overvolle treinen. Met de Regio Deal gaan we deze uitdagingen samen te lijf, zodat we ook in de toekomst gezond kunnen wonen en werken in één van de snelst groeiende regio’s van het land.”

Voor de totstandkoming van deze Regio Deal stelt het Rijk 15 miljoen euro beschikbaar. Ondernemers, bedrijfsleven, onderwijs- en kennisinstellingen, maatschappelijke organisaties, gemeenten en de provincie leggen zelf ook minimaal 15 miljoen euro in. De verwachting is dat de eerste projecten begin 2024 van start gaan.

Regio Deal – Gezonde Groene Groei

Podcast AI for Life: AI and electrical grids

AI-innovaties manifesteren zich steeds nadrukkelijker in het dagelijks leven. Ze analyseren medische beelden, ze staan je te woord (chatbots), ze lezen en reageren op je emoties, ze filteren zinvolle informatie uit enorme databergen, ze besturen robots in de zorg… In deze serie podcasts ‘AI for Life’ vertellen top-experts over de laatste ontwikkelingen in AI, die ze hier en nu zelf vormgeven.

Luister hier de podcast.

TOPX Summit

Closing the Gap

18-19 January 2024 | Utrecht

Empowering Women to Rise to the Top in Life Sciences & Health

Join us on January 18th and 19th, 2024, at the Accelerator of Kadans in Utrecht for the next edition of TOPX Summit. This two-day summit is aimed at fostering diversity and inclusivity within the Life Sciences & Health sector, by empowering women to rise to the top.

With the mission to create a more diverse and inclusive top tier of professionals in the sector, TOPX Summit 2024 will focus on “Closing the Gap” in various fields. We will strive for leadership balance, fostering alignment in perspectives between different genders, generations and cultures, and tackle critical issues such as closing the gender health gap, the pay gap and the wealth gap.

Prepare for inspiring keynote presentations, insightful sessions, interactive workshops, engaging panel discussions, deep dives, 1-on-1 speed dates, coaching sessions and invaluable networking opportunities with accomplished and upcoming leaders.

Join us for TOPX Summit 2024 and be part of this transformative experience on January 18th and 19th, 2024, in Utrecht. Together, let’s close the gaps and build a more inclusive future in Life Sciences & Health. More info and programme.

Health Valley Event 2024

Transition in Healthcare

Het Health Valley Event op 21 maart 2024 in Pathé Nijmegen is hét meest vooruitstrevende zorginnovatie event van Nederland en tevens dé ontmoetingsplaats voor iedereen die zich bezighoudt met innovaties, business en wetenschap in de Life Sciences & Health sector.

Samen zorgen voor morgen

Goede betaalbare gezondheidszorg nu en in de toekomst, dat is waar we allemaal naar streven. Technologische innovaties spelen hierbij een steeds grotere rol en zorgen ervoor dat de zorg uitvoerbaar, betaalbaar en van hoge kwaliteit blijft. Op het Health Valley Event draait het om deze innovaties in de zorg.

Kennisinstellingen, zorginstellingen, ondernemers en overheden, we hebben allemaal met de transitie in de zorg te maken en dragen allen ons steentje bij. Op het Health Valley Event gaan we samen in gesprek over toekomstbestendige zorg en de technologische innovaties die hieraan bijdragen.

We praten je bij over de laatste trends en ontwikkelingen, inspireren je met mooie voorbeelden en bieden je unieke netwerkkansen om met elkaar invulling te geven aan de transitie richting toekomstbestendige zorg. Kortom, een vol en gevarieerd programma op 21 maart!

Mis deze dag niet en meld je snel aan! Omdat wij als Briskr samen met The Economic Board in een stand aanwezig zijn (standnummer 28) kunnen we je een korting geven van 25% op een ticket. Wil je hier gebruik van maken, stuur ons dan een e-mail via info@briskr.nl.

Meer info over het Health Valley Event vind je hier.

Webinar Winstgevende strategieën om zaken te doen in Duitsland

Wil je winstgevende kansen benutten in Duitsland, een belangrijke exportmarkt en handelspartner in Europa? Dan is dit webinar iets voor jou!

Duitsland is niet alleen een belangrijke exportmarkt, maar ook een centrum van innovatie en zakelijke groei. Met een strategische benadering kun je jouw omzet en winst in deze markt maximaliseren.

Tijdens het webinar zullen de volgende onderwerpen behandelt worden:

– Marktanalyse: kansen voor groei en omzetverhoging in de Duitse markt

-Juridische en regelgevende aspecten: juridische vereisten en regelgeving voor Duitse handel.

-Culturele inzichten: opbouw effectieve zakelijke relaties in Duitsland

-Strategische planning: solide strategie voor duurzaam succes

-Praktische tips

De experts Lizanne Jakobs, bedrijfscoach en Nicki Welchering, Rechtsanwalt delen hun ervaringen en zullen al jouw vragen beantwoorden omtrent jouw markttoetredingsstrategie voor Duitsland.

Dit gratis webinar biedt een uitgelezen gelegenheid om jouw positie in de Duitse markt te versterken en lucratieve handelskansen te verkennen. Wacht niet te lang en meld je snel aan.

Lizanne Jakobs en Nicki Welchering geven tijdens en na afloop van de presentaties antwoord op al jouw vragen.

Sprekers:

Lizanne Jakobs, bedrijfscoaches en adviseurs, Brilliant Work, www.brilliantwork.nl

Nicki Welchering, Rechtsanwalt, ALPMANN FRÖHLICH Rechtsanwälte & Notare, www.alpmann-froehlich.nl

Hoe werkt het:

Het webinar vindt plaats op vrijdag 8 december 2023 van 12.30 uur t/m 13.30 uur.

Bij aanmelding ontvangt je een link waarmee je toegang krijgt tot het online seminar. Je hoeft het programma Teams niet op je computer te installeren, je kunt deelnemen via een weblink.

Deelname:

Aan de deelname van dit online seminar zijn geen kosten verbonden. Het online seminar wordt in het Nederlandse gehouden. Meld je via deze link aan.

SMB Network Meeting Transforming (elderly) care together

Healthcare is on the brink of a crisis. Without intervention the number of people working in healthcare would grow from 1 in 7 employees to 1 in 4, straining our labor market to its limits. The main cause is the ageing society and a shrinking pool of young healthcare workers.

You can also say we’re facing a potential, especially in elderly care. It’s time for innovative solutions! Technology can support this. However, we won’t solve the labor market problems with more innovative technology alone. A transformation of care is needed and this cannot be done from 1 sector alone. We also need cutting-edge living and care models that boost independence and harness the power of informal care. To succeed, it is necessary to pair up with all parties active in in the field of health care and the living environment.

During this SMB meeting we will discuss several regional actions to fundamentally improve (elderly) care including the digital health challenge lab (DHCL).

In DHCL the frustrations and desires (challenges) of residents, housing associations, healthcare professionals, healthcare organizations around their (own) health, healthcare supply and the healthcare process are collected, answered and solved. On the basis of these challenges, companies can specifically develop innovative products and/or services for which there is actual demand and support. After all, a challenge is a problem with a business case!

Date: January 25, 2024
Registration: 15:30
Program: 16:00-17:00 hrs (+ networking, drinks & bites)
Location: Noviotech Campus Nijmegen, building M, Meet&Greet area

Live event
This event will be organized in a live setting at Noviotech Campus in Nijmegen (building M, Meet&Greet area). A few days before the event we will send an email with practical information on directions/parking (sender = smb@radboudumc.nl). You might have to check your spam box.

Good to know
Presentations are in English & the entrance is free (registration upfront is needed though). We welcome new guests, so please feel free to pass on this invitation to relevant people in your network!

We look forward to meet you!

Please register upfront here.

BANN, Business Angels Network Nijmegen

The Business Angels Network Nijmegen (BANN) is an initiative from Briskr and OostNL to connect angel investors with promising startups in health and hightech in the metropole region Arnhem-Nijmegen. In three events per year 12 startups in total are giving the opportunity to pitch their business idea and investment opportunity to an audience of interested investors. The normal range of investment is between 50K to 300K but in some cases a combination can be made with other investment channels. The event is invite only.

The meetings are held a Slot Doddendael in Ewijk (next to Nijmegen), start around 16:00 and are combined with dinner until 20:00.

For investors

The BANN is a network of 100+ investors interested in health and hightech sectors. Of these normally around 40 investors are present during the meetings. Before the meeting you will receive information about the startups to determine if a visit is justified. Beside the investment opportunities the BANN is also a social gathering including plenty of opportunity to network with other angels during dinner.

Interested investors and startups can contact Bart Heuts (bart.heuts@oostnl.nl)

How to get accepted for reimbursement by Dutch healthcare system?

Brilliant business models in healthcare

As a healthcare entrepreneur, you might possess an excellent product designed to enhance healthcare quality and efficiency. However, selling it could prove challenging. The adoption of new technologies is a decision that involves healthcare organizations, professionals, insurance companies, and occasionally, even patients. The separation of costs and returns, often residing in different hands, complicates the reimbursement process. Consequently, this complexity may lead to a diminished interest from potential investors.

Reimbursement
This workshop will focus on reimbursement in healthcare systems in general and specifically on the Dutch healthcare system. It will give insight in the way the healthcare system is organized and what you should know if you want to get reimbursementfor your innovation!

What’s in it for me?
Jeroen will also show a lot of examples of the sort of brilliant business models which are needed to improve healthcare and realize the quadruple aim: better health, nicer treatment, happier healthcare workers and reduced cost. And then it’s time to apply the information to your own business case! There will be ample time to discuss, improve and refine your individual case with Jeroen and the other attendees.

About Jeroen
Jeroen Kemperman is sr. Manager Strategy & Business Development at Achmea/Zilveren Kruis and writer of several books on business models. He does this from his background in industrial engineering as well as from his practical perspective of working in healthcare. For his books he has researched working business models in the complex world of world-wide healthcare.

During the workshop we will hand out the recommended book ‘Brilliant business models in Healthcare’ from Jeroen Kemperman, Jeroen Geelhoed & Jennifer op ’t Hoog (or in Dutch: ‘Briljante Businessmodellen in de Zorg’).

We charge a small fee of €50,- (invoice) to cover the expenses of this book.

Location
Noviotech Campus Nijmegen, building M, Meet&Greet area. Transistorweg 5

Good to know
Participation in the workshop is free for everyone, including drinks and bites. However, for cancellations within 24 hours prior to the event, we will charge a fee of 15 euros (excluding VAT) to cover incurred expenses.

We welcome new people, so feel free to share this invite with your network!

EU Clinical Trials Regulation and Clinical Trials Information System

Discover an informative webinar to unravel the complexity of the Clinical Trials Information System (CTIS) and explore the regulatory structure in Europe. Most importantly, let’s discuss whether all the latest changes in the regulatory landscape still position Europe as the number one destination for clinical trials.

The implementation of the clinical trial regulation 536/2014 (Regulation (EU) No 536/2014, on January 31, 2022, was aimed at making the European Union (EU) a more attractive destination for pharmaceutical research and development. But is this the current status for EU manufacturers? This regulation focuses on harmonizing processes of clinical trials including submission, application for authorization, evaluation and supervision of clinical trials within the EU and the European Economic Area, thereby increasing transparency towards the public and providing a common database for regulators. Sponsors of clinical trials are now required to submit their trial via the CTIS portal for regulatory oversight of the trial, tools and monitoring of the trial.

However, since the implementation of CTIS, manufacturers have faced new challenges and regulators are overwhelmed with its complexity.

As a clinical research organization (CRO) that is also able to take over the role of a sponsor for clinical trials, GCP-Service has experienced CTIS firsthand. Join this webinar to gain insights into:
– The complexity of CTIS
– Was Europe ready for CTIS?
– Did the implementation of CTIS destroy theclinical trial environment in the EU?
– Does CTIS simplify the submission process?
– Issues and improvements on the CTIS platform

Speakers are:

Dr. Andreas Beust, CEO, GCP-Service International

Dr. Andreas Beust is Chief Executive Officer of GCP-Service International, President of the Association of International CROs (AICROS), and a passionate advocate of optimizing trial design and conduct. Andreas is intimately familiar with the requirements of clinical trials on European and international levels, both from the CRO side and by taking on sponsorship responsibility for investigator-led trials and has participated in more than 80 trials to date. As an ambassador for risk-based quality management, he focuses on consulting drug and medical device manufacturers alike on how to conduct lean, efficient trials that focus on what is important while adhering to regulatory requirements.

Dr. Jan Willem Kleinovink, Scientific staff member, CCMO (Dutch Competent Authority)

Dr. Jan Willem Kleinovink joined CCMO, the Dutch Competent Authority on clinical trials located in The Hague, after doing academic research in immuno-oncology. At CCMO, he is clinical assessor, validation team lead, and provides support and training on CTIS applications to both authority and sponsor users. In these roles, he experiences the practical and strategic challenges, but also the advantages, of the CTR and CTIS on a daily basis. He uses these experiences to advise on improvements in both the CTIS portal and in the international harmonization of validation and assessment of clinical trial applications.

So join and find out more: EU Clinical Trials Regulation and Clinical Trials Information System – Xtalks

Recap of Briskr Academy workshop: What is the value of your company?

Navigating the complex realm of business valuation is a challenging task. Especially for startups with limited historical data to base your valuation on. We offer workshops every year to help startups understand how valuation works, how to best prepare for negotiations, and how to set terms between you and the investor. We look back at the workshop held on 28 September: Company Valuation & Legal Issues of Joint Ventures with Investors and discuss why valuation is so important for startups and what terms are essential.

Whatever stage your company is at, valuation is a pre-condition for external financing and, thus, for moving forward. John van Zandbergen, CEO of Ourobionics, explains the importance of investors: “We are using deep technology to enable human tissues and organs to become cyborganic, transforming regenerative medicine. Since our founding in 2021, we have been through a number of valuation processes. We find that the value investors place on your startup is very different. There are many different valuation models, and I would like to know on what basis such a valuation is done.”

The CEO of Exolumen adds: “We have developed a product to project anatomy onto the human body in order to reduce complications during surgery. It is a promising product, but it’s difficult to determine the value of our startup. For investors, this is business as usual, but for startups it is new. So any information I can get on the subject is interesting. For example, how can you get an indication of your company’s value? Google helps, of course, but in a workshop, you learn a lot more from speakers from the field.”

Sharing their knowledge

There were three speakers at the workshop to delve into the topic of ‘Company valuation & legal issues of joint ventures with investors’. Bram ten Bok of Oost NL, Sjoerd Klabbers of BDO and Emile Sahhar of Poelmann van den Broek Lawyers.

Ten Bok was the first speaker. As Investment Manager Health at Oost NL, he talked about the valuation process from an investor’s perspective. “Both investors and entrepreneurs want a deal that makes them happy,” explains Ten Bok. “In order to have fruitful discussions about company valuation, it’s important for both sides to have a good understanding of each other’s perspective. I am here today to answer questions such as: ‘What does an investor look for in a business case?’ and ‘What is expected of you as an entrepreneur?’”

“Naturally, an investor wants a good return on his investment. This is often difficult for startups in the health and high-tech sector because a lot of upfront investment is needed before your product can reach the market. This is why investors need to get a good feel for the startup and its growth potential.”

Next up is Klabbers from BDO. “As a consultant at BDO, I deal with company valuations and buy-and-sell on a daily basis. Startups are the new engine of the economy, so I think it’s important to be here today. This way, I can help our region by explaining exactly how such a valuation is done, what methods are available and what pitfalls startups may encounter.”

Finally, Sahhar takes the microphone. “As a lawyer and salary partner at Poelman van den Broek, I deal with mergers, acquisitions and related legislation on a daily basis. I like to help founders by sharing my knowledge. For example, what can go wrong between an entrepreneur and an investor in a company? Thorough consideration of these issues will help ensure a smooth relationship between the entrepreneur and the investor.”

Positive reactions

After the workshop, the startups gained some useful insights into the valuation world. This leads to enthusiastic reactions, for example from Exolumen’s CEO: “It was very positive for me. There was a lot of room for interaction and questions. It is a very technical subject, but it was explained in a way everyone could understand. It was interesting to hear how investors think and what is important to them. Sometimes you forget that you have to think from their point of view as well, to be more in tune with what is important to them. That helped me a lot. These are points that I will think about when I’ll have a conversation with a potential investor. All in all, the workshop made a very positive contribution!”

Check out our event calender to see when the next workshop ‘Company valuation & legal issues of joint ventures with investors’ is planned!